IASLC World Conference on Lung Cancer | Conference

Liposomal Irinotecan Active in Small Cell Lung Cancer

September 13th 2019

Liposomal irinotecan achieved disease control in almost half of patients as a second-line treatment for small cell lung cancer, according to findings from Part 1 of the phase II/III RESILIENT trial presented at the 2019 World Conference on Lung Cancer.

DS-1062 Elicits Intriguing Early-Phase Data in Advanced NSCLC

September 12th 2019

The investigational Trop-2–targeting antibody-drug conjugate DS-1062 demonstrated antitumor activity in unselected patients with unresectable, advanced non–small cell lung cancer.

Dr. Campelo on the Rationale for the ALTA-1L Trial

September 11th 2019

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.

Dr. Carbone on Pivotal Immunotherapy Studies in Lung Cancer

September 11th 2019

David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.

Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLC

September 11th 2019

Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.

Mutation-Defined Lung Cancer Trial Yields Hits and Misses for Targeted Therapy

September 11th 2019

Targeted therapies for non–small cell lung cancer produced mixed results in a novel multiarm clinical trial that matched tumor mutations to drugs targeting the mutations.

Atezolizumab Combo Shows Clinical OS Benefit in PD-L1-High Squamous NSCLC

September 10th 2019

The addition of atezolizumab (Tecentriq) to carboplatin and nab-paclitaxel (Abraxane) showed a clinical overall survival benefit among a subgroup of patients with advanced squamous non–small cell lung cancer.

Nivolumab Continues to Demonstrate Encouraging OS Rates in NSCLC at 5 Years

September 10th 2019

Treatment with nivolumab (Opdivo) was associated with a 5-year overall survival rate of 13.4% compared with 2.6% with docetaxel in patients with previously treated non–small cell lung cancer.

Dr. Drilon on Results of the Phase I/II LIBRETTO-001 Trial

September 10th 2019

Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.

Dr. Langer on the Future of Immunotherapy for Treatment of NSCLC

September 10th 2019

Corey J. Langer, MD, director, thoracic oncology, Penn Medicine, discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

Dr. Tolba on Targeting NRG1 Fusions in NSCLC

September 10th 2019

Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non-small cell lung cancer.

Larotrectinib Is Highly Active in Patients With NTRK Fusion+ NSCLC

September 10th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine, Harvard Medical School, discusses the updated activity of larotrectinib in NTRK fusion–positive lung cancer.

Selpercatinib Achieves High Response Rate in RET+ NSCLC

September 10th 2019

Almost 70% of patients with previously treated RET-fusion–positive non–small cell lung cancer had objective responses to the RET inhibitor selpercatinib (LOXO-292), according to data from the phase I/II LIBRETTO-001 trial presented at the 2019 World Conference on Lung Cancer.

Durvalumab Combo Improves Survival in Frontline Small Cell Lung Cancer

September 9th 2019

Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.

Afatinib Continues to Showcase Activity in NRG1 Fusions in Lung Cancer

September 9th 2019

Findings from a small case series of patients with lung cancer added to evidence that afatinib is a potentially effective treatment in patients with lung adenocarcinoma who have NRG1 fusions.

Bemcentinib/Pembrolizumab Combo Active in Chemo-Refractory NSCLC

September 9th 2019

The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.

Expert Discusses Novel Agents in Development Targeting EGFR, HER2+ NSCLC

September 9th 2019

Pasi A. Jänne, MD, PhD, discusses 3 studies of novel agents for targeting EGFR-mutant and HER2-positive lung cancers and the next steps in getting the research to cancer clinics.

AMG 510 Highly Active in KRAS+ NSCLC

September 8th 2019

The investigational KRAS inhibitor AMG 510 induced near-universal disease control in patients with advanced non–small cell lung cancer with KRAS mutations.

Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer

November 1st 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer

November 1st 2017

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.